334 The importance of prognostic parametres for the allogeneic transplantation course in patients with myelodysplastic syndromes and secondary acute leukemia von Vondráková, J, Bělohlávková, P, Zapletalová, J, Raida, L, Žák, P, Jebavý, L, Voglová, J, Zavřelová, A, Lánská, M, Pikalová, Z, Skoumalová, I, Jarošová, M, Faber, E, Malý, J, Indrák, K

Volltext

CO77 Impact of Imetelstat Treatment on PROs and Health Care Resource Utilization in Heavily Transfused Non-Del(5Q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Eryth... von Sekeres, M., Santini, V., Diez-Campelo, M., Komrokji, R., Fenaux, P., Savona, M., Madanat, Y., Valcárcel-Ferreiras, D., Illmer, T., Jonášová, A., Bělohlávková, P., Regnault, A., Creel, K., Sengupta, N., Sherman, L., Berry, T., Dougherty, S., Shah, S., Xia, Q., Sun, L., Wan, Y., Huang, F., Ikin, A., Navada, S., Feller, F., Zeidan, A., Platzbecker, U.

Volltext

Prognostic factors affecting the outcome after allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome von Belohlavkova, P, Vrbacky, F, Smolej, L, Radocha, J, Lanska, M, Visek, B, Kupsa, T, Zavrelova, A, Zak, P

Volltext

103 AZACITIDINE TREATMENT OF HIGH RISK MDS AND AML, ANALYSIS OF LONG RESPONDING PATIENTS AND PROGNOSTIC FACTORS OF OVERALL SURVIVAL, CZECH MDS GROUP EXPERIENCE von Jonasova, A, Cermak, J, Cervinek, L, Belohlavkova, P, Cerna, O, Kacmarova, K, Janousova, E

Volltext

Topic: AS02-Epidemiology von Jonasova, A., Belohlavkova, P., Cervinek, L., Cermak, J., Dusilkova, N., Baranova, J.

Volltext

P08 - Topic: AS02-Epidemiology: TEN YEARS OF THE CZECH MDS REGISTRY: REAL LIFE DATA AND EXPERIENCES von Jonasova, A., Belohlavkova, P., Cervinek, L., Cermak, J., Dusilkova, N., Baranova, J.

Volltext

211 Deferasirox vs. deferiprone treatment in iron overloaded patients with myelodysplastic syndrome – a study on 113 patients with low-risk MDS von Cermak, J, Jonasova, A, Vondrakova, J, Cervinek, L, Belohlavkova, P, Sponerova, D, Novakova, L, Walterova, L, Neuwirtova, R

Volltext

175 Czech MDS Group experience with azacitidine in treatment of high risk MDS and AML patients von Jonasova, A, Cermak, J, Cervinek, L, Novakova, L, Vondrakova, J, Belohlavkova, P, Sykora, M, Seifertova, N, Walterova, L, Libiger, J, Michalova, K, Zemanova, Z, Brezinova, J, Kacmarova, K, Klapka, R

Volltext

274 The response of FLi1, EKLF, TP53 (p53), PU.1, MDM2 gene expression in 5q- syndrome to lenalidomide treatment von Jonasova, A, Fuchs, O, Vostry, M, Holicka, M, Kostecka, A, Cermak, J, Caniga, M, Kobylka, P, Siskova, M, Cervinek, L, Belohlavkova, P, Sykora, M, Zemanova, Z, Michalova, K, Brezinova, J, Neuwirtova, R

Volltext

247 miRNA expression profiling in 5q- syndrome patients treated with lenalidomide von Krejcik, Z, Merkerova, M. Dostalova, Belickova, M, Cermak, J, Michalova, K, Zemanova, Z, Cervinek, L, Belohlavkova, P, Sykora, M, Libiger, J, Neuwirtova, R, Jonasova, A

Volltext

301 Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q- MDS (IPSS low and Intermediate-1) von Jonasova, A, Cermak, J, Vondrakova, J, Siskova, M, Hochova, I, Kadlckova, E, Cerna, O, Sykora, M, Vozobulova, V, Seifertova, N, Michalova, K, Zemanova, Z, Brezinova, J, Belohlavkova, P, Neuwirtova, R

Volltext

228 Lenalidomide treatment of patients with 5q- syndrome affects genes located in the TNF pathway von Belickova, M, Cermak, J, Vesela, J, Cechova, E, Dostalova-Merkerova, M, Krejcik, Z, Michalova, K, Zemanova, Z, Cervinek, L, Belohlavkova, P, Sykora, M, Libiger, J, Neuwirtova, R, Jonasova, A

Volltext

P075 Characteristics of patients with therapy-related myelodysplastic syndrome von Belohlavkova, P, Voglova, J, Neuwirtova, R, Krejcova, H, Cermak, J, Vondrakova, J, Vozobulova, V, Krejci, M, Muzik, J

Volltext

P081 The questions on megakaryopoiesis in MDS patients with del(5q) von Neuwirtova, R, Jonasova, A, Cermak, J, Vondrakova, J, Hochova, I, Jungova, A, Belohlavkova, P, Siskova, M, Kadlckova, E, Cerna, O, Smolikova, A, Polonyova, E, Bruchova, H, Zemanova, Z, Mikulenkova, D

Volltext

PO015 Therapy-related MDS/AML after von Belohlavkova, P, Zavrelova, A, Zak, P, Cermanova, M, Belada, D, Voglova, J, Jebavy, L, Maly, J

Volltext

Is it Important to Perform Liver Biopsy After Allogeneic Transplantation? von Zak, P, Zavrelova, A, Cermanova, M, Jebavy, L, Belohlavkova, P

Volltext

Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia – the Retrospective Analysis von Vondrakova, J, Belohlavkova, P, Zapletalova, J, Raida, L, Zak, P, Jebavy, L, Voglova, J, Zavrelova, A, Pikalova, Z, Skoumalova, I, Jarosova, M, Faber, E, Maly, J, Indrak, K

Volltext

Prognostic factors affecting the outcome after allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome von Belohlavkova, P, Vrbacky, F, Smolej, L, Radocha, J, Lanska, M, Visek, B, Kupsa, T, Zavrelova, A, Zak, P

Volltext

Magnetic Resonance Imaging Techniques for Indirect Assessment of Myelin Content in the Brain Using Standard T1w and T2w MRI Sequences and Postprocessing Analysis von POKOŠOVÁ, P, KALA, D, ŠANDA, J, JEŽDÍK, P, PRYSIAZHNIUK, Y, FARIDOVÁ, A, JAHODOVÁ, A, BĚLOHLÁVKOVÁ, A, KALINA, A, HOLUBOVÁ, Z, JURÁŠEK, B, KYNČL, M, OTÁHAL, J

Volltext

Trends in paediatric epilepsy surgery 2000–2016 von Bělohlávková, A, Ježdík, P, Kudr, M, Jahodová, A, Maulisová, A, Komárek, V, Libý, P, Tichý, Michal, Kršek, P

Volltext